VECTUS BIOSYSTEMS LIMITED — Board/Management Information 2016

May 4, 2016

==> picture [141 x 43] intentionally omitted <==

5 May 2016

Company Announcements Office Australian Securities Exchange

Board Appointment

Vectus Biosystems Limited (ASX:VBS) is pleased to announce the appointment of Dr Susan Pond as a new member of the Board of the Company, effective from 4 May 2016.

Dr Susan Pond AM, MD, DSc, FTSE, FAAHMS Non-Executive Director

Dr Pond has a strong scientific and commercial background, having held executive positions in the biotechnology and pharmaceutical industry for 13 years, including as Chairman and Managing Director of Johnson & Johnson Research Pty Limited (2003 to 2009). She was Non-Executive Director and Chairman of AusBiotech Limited (2004 to 2008); Director of the Centenary Institute of Cancer Medicine and Cell Biology (2009 to 2014); Director of the Australian Nuclear Science and Technology Organisation (2010 to 2014); Board member of Innovation Australia (2012 to 2015) and Commercialisation Australia (2010 to 2013); and Vice President of the Australian Academy of Technological Sciences and Engineering Limited (2010 to 2015).

Dr Pond is a Fellow of the Australian Institute of Company Directors, the Academy of Technological Sciences and Engineering, and the Australian Academy of Health and Medical Sciences. She holds a first class honours degree in Bachelor of Medicine and Surgery from the University of Sydney, a Doctor of Medicine degree from the University of New South Wales and a Doctor of Science degree from the University of Queensland. Dr Pond obtained specialist clinical credentials in internal medicine, clinical pharmacology and clinical toxicology, has held academic appointments at the University of California in San Francisco and the University of Queensland, and was Chairman of the Australian Drug Evaluation Committee (1994 to 1996). She has been a Director of Biotron Limited (ASX:BIT) since 7 March 2012.

The Board welcomes Susan as a new Director of Vectus Biosystems Limited and looks forward to her contribution to the growth of the Company. Her Appendix 3X is attached.

Vectus Biosystems Limited

Robert J Waring Company Secretary

About Vectus Biosystems Limited

Vectus Biosystems Limited (Vectus or the Company) is developing a treatment for fibrosis and high blood pressure, which includes the treatment for three of the largest diseases in the fibrotic market, namely heart, kidney and liver disease. Vectus successfully completed its Initial Public Offering (IPO) on the Australian Securities Exchange (ASX) and commenced trading on ASX on 23 February 2016, after raising A$5.1 million. Funds from the IPO are being used to develop the Company’s lead compound VB0004, which aims to treat the hardening of functional tissue and high blood pressure. Vectus has conducted a range of successful pre-clinical trials, which have shown that VB0004 slows down the advances of fibrosis, potentially repairs damaged cell tissue and reduces high blood pressure. VB0004 is now progressing towards a number of important milestones, including pharmaceutical scale-up and additional toxicity studies. Successful results will provide the Company with a clear path to Human Phase I and IIa Clinical Trials. Vectus’ strategy is to develop and perform early validation of its drug candidates to the point where they may become commercially attractive to potential pharmaceutical partners.

The Company has also developed technology aimed at improving the speed and accuracy of measuring the amount of DNA and RNA in samples tested in laboratories. The technology, called Accugen, is owned by Vectus’ whollyowned subsidiary Accugen Pty Limited. The technology potentially offers a time, cost and accuracy benefit compared to currently-available systems. The Company’s next stage of investment in Accugen will focus on an Alpha-phase test programme during 2016 before moving to a commercialisation programme that may include direct sales, distribution partnerships and licencing opportunities.

VECTUS BIOSYSTEMS LIMITED ABN 54 117 526 137

3-11 Primrose Avenue, Rosebery, NSW 2018 Telephone: +61 2 9662 4144 Facsimile: +61 2 9697 0933 Website: www.vectusbiosystems.com.au

Appendix 3X Initial Director’s Interest Notice

Rule 3.19A.1

Appendix 3X

Initial Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/9/2001.

Name of entity Vectus Biosystems Limited (ASX:VBS) ABN 54 117 526 137

We (the entity) give ASX the following information under listing rule 3.19A.1 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Susan Margaret Pond
Date of appointment	4 May 2016

Part 1 - Director’s relevant interests in securities of which the director is the registered holder In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Number & class of securities

Nil

Part 2 – Director’s relevant interests in securities of which the director is not the registered holder In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

	Name of holder & nature of interest Note: Provide details of the circumstances giving rise to the relevant interest.	Number & class of Securities Nil

• See chapter 19 for defined terms.

Appendix 3X Page 1

11/3/2002

Appendix 3X Initial Director’s Interest Notice

Part 3 – Director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	Not Applicable
Nature of interest	Not Applicable
Name of registered holder (if issued securities)	Not Applicable
No. and class of securities to which interest relates	Not Applicable

• See chapter 19 for defined terms.

Appendix 3X Page 2

11/3/2002